Evaluation of the Quality of Life of Patients With DBB With the Installation of OPEP

NCT ID: NCT06820983

Last Updated: 2026-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-17

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To carry out an assessment of compliance and quality of life in a population (children and adults) with DDB before and after the use of an oscillating PEP. The aim is to determine the impact of the use of oscillating PEP on the daily life of this population in particular.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis Quality of Life Physiotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adult questionnary for parents of children aged 8 to 13

Quality of life questionnaire for parents of children aged 8 to 13

Intervention Type OTHER

Quality of life questionnaire for children aged 8 to 13

Quality of life questionnaire for children aged 8 to 13

Intervention Type OTHER

Quality of life questionnaire for adolescents aged 14 to 17

Quality of life questionnaire for adolescents aged 14 to 17

Intervention Type OTHER

Quality of life questionnaire for adults

Quality of life questionnaire for adults

Intervention Type OTHER

A satisfaction adherence questionnaire

A satisfaction adherence questionnaire will also be distributed to patients after several months' use of oscillating PEP

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children (from 8 years of age) and adults over 18 years of age with DDB who doesn't use oscillating PEP.

The study population will be clinically stable and will be seen in follow-up consultations.

Exclusion Criteria

* Children under 8 years of age.
* Patients who use an OPEP
* Patients in the acute exacerbation phase of their DDB
* Patients who are not under regular consultation
* Patients with severe, uncontrolled co-morbidities
* Patients with cognitive or psychiatric disorders preventing proper adherence to the study protocol
* Patients taking part simultaneously in another clinical study that could interfere with the results of the OPEP study
Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hôpital Armand Trousseau

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens-Picardie

Amiens, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas PINTO, MD

Role: CONTACT

33+3 22 08 80 00

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Pinto, MD

Role: primary

33+22088000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI2024_843_0118

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.